GENZYME CORPORATION for GENZYME CORPORATION
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Funding for FDA and NIH FY 2015 Budget
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
Taxation/Internal Revenue Code TAX
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax CreditImplementation of American Taxpayer Relief Act of 2012 Tax Reform H.R. 4438, American Research and Competitiveness Act of 2014
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
Health Issues HCR
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Health Technology Assessment of Orphan DrugsH.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013 H.R. 2090, Patient Choice Act of 2013 H.R. 4475, Compassionate Freedom of Choice Act of 2014 H.R. 1239, Accessing Medicare Therapies Act of 2013 H.R. 460, Patients' Access to Treatments Act of 2013
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
Medicare/Medicaid MMM
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 H.R. 4302, Protecting Access to Medicare Act of 2014
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
Pharmacy PHA
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Naming of Biosimilars Guidance Implementation of Drug Quality and Security Act
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.